|
|
|
|
Search: 
Latin American Herald Tribune
Venezuela Overview
Venezuelan Embassies & Consulates Around The World
Sites/Blogs about Venezuela
Venezuelan Newspapers
Facts about Venezuela
Venezuela Tourism
Embassies in Caracas

Colombia Overview
Colombian Embassies & Consulates Around the World
Government Links
Embassies in Bogota
Media
Sites/Blogs about Colombia
Educational Institutions

Stocks

Commodities
Crude Oil
US Gasoline Prices
Natural Gas
Gold
Silver
Copper

Euro
UK Pound
Australia Dollar
Canada Dollar
Brazil Real
Mexico Peso
India Rupee

Antigua & Barbuda
Aruba
Barbados
Cayman Islands
Cuba
Curacao
Dominica

Grenada
Haiti
Jamaica
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines

Belize
Costa Rica
El Salvador
Honduras
Nicaragua
Panama

Bahamas
Bermuda
Mexico

Argentina
Brazil
Chile
Guyana
Paraguay
Peru
Uruguay

What's New at LAHT?
Follow Us On Facebook
Follow Us On Twitter
Most Viewed on the Web
Popular on Twitter
Receive Our Daily Headlines


  HOME | Argentina

Argentine Equine Serum Effective, Safe for COVID-19 Cases

BUENOS AIRES – The hyperimmune serum produced from horses in Argentina completed the last phase of its clinical studies and “demonstrated efficacy and safety” in serious COVID-19 cases, according to a statement issues by the government on Monday.

Hyperimmune serum is blood plasma containing high amounts of an antibody.

This particular serum, distribution of which will begin this week throughout the country, “is an immunotherapy based on equine polyclonal antibodies, which blocks the neutralizing capacity of the SARS-CoV-2 virus and prevents its propagation,” and in addition “it has the advantage that it can be produced quickly and on a large-scale basis,” the statement said.

The clinical study – on the basis of which the National Medicines, Foods and Medical Technology Administration (ANMAT) approved its use on Dec. 22 – achieved positive results in lowering mortality (45 percent), reducing the number of required days of intensive therapy (24 percent) and reducing the need for the use of ventilators (36 percent).

The study evaluated the safety and efficacy of the drug in 242 patients aged 18-79 with moderate to severe illness caused by COVID-19, as confirmed by a PCR test, within 10 days of the onset of symptoms and requiring hospitalization.

President Alberto Fernandez visited on Monday the facilities of the Inmunova biotechnology firm on the campus of the San Martin National University, which together with other public and private scientific centers developed the serum, which will now be distributed to hospitals, clinics and sanatoriums, and he expressed his “pride” over the results that had been achieved.

Production of the serum is the result of a public-private effort headed by the Inmunova lab, the Argentine Biological Institute and the Dr. Carlos G. Malgran National Laboratories and Health Institutes Administration.

The serum project was one of the 84 initiatives selected by the government for co-participation and financing of $100,000, and within the span of 10 months researchers managed to create a serum that prevents the coronavirus from entering cells in lab tests.

Health care workers were at the head of the line on Dec. 29 as Argentina began nationwide COVID-19 vaccinations using Sputnik V, developed by Russia’s Gamaleya Research Institute. The first 300,000 doses arrived in Argentina on Dec. 24 and then were delivered to distribution points around the country on Dec. 28.

Russia has faced criticism for authorizing use of Sputnik V prior to the conclusion of large-scale clinical trials.

As of Sunday, more than 1.72 million Argentines had been officially confirmed as COVID-19 cases and 44,495 of them had died.

 

Enter your email address to subscribe to free headlines (and great cartoons so every email has a happy ending!) from the Latin American Herald Tribune:

 

Copyright Latin American Herald Tribune - 2005-2021 © All rights reserved